Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Azilect, Rasalect
Rasagiline is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) used as monotherapy or as an adjunct to levodopa in the treatment of Parkinson's disease. It helps increase dopamine levels in the brain, thereby improving motor control and reducing symptoms like tremors, rigidity, and slow movement.
For the treatment of Parkinson's disease, either as monotherapy or as an adjunct to levodopa.
Outcome:
Serotonin syndrome
Mechanism:
Increased serotonin levels due to MAO-B inhibition
Outcome:
Serotonin syndrome
Mechanism:
Increased serotonin levels
Outcome:
Increased blood pressure
Mechanism:
Increased norepinephrine release
Most likely new formulation: Extended-release formulation (Year: 2026, 70% confidence)
Based on current usage trends and clinical trial data, there is a low likelihood of any major regulatory changes in the next 2 years (85% confidence).
MAO-B Inhibitor
Propargylamine